De novo macrocyclic peptide discovery produces potent class A GPCR ligands with diverse pharmacology
Fernando Salgado-Polo, Marin Matic, Philip Rainsford…·Martin B Gustavsson
This study discovers potent, selective macrocyclic peptide ligands for CXCR4, a class A GPCR, demonstrating the feasibility of de novo peptide design for this receptor family.